… Of note, naso-pharyngeal control swab test for SARS-CoV-2 resulted positive 2 months after
… by SARS-CoV-2 infection. Neck pain was absent, but the patient was under high doses of …

… By 7th March, the infection of SARS-CoV-2 has influenced … Here we compared the viral
shedding time of SARS-CoV-2 … performed RT-PCR tests targeting SARS-CoV-2. The continuous …

… The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has … Mutated SARS-CoV-2 variants with enhanced …

… Among patients randomized to the lower dosage group (5 days of treatment, total dose 2.7
g), given the limited number of patients so far enrolled, it is still not possible to estimate a clear …

… At the lower doses of the mAbs we tested, we observed some differences in mAb cocktail
efficacy between rodent models, which could be due to host variation, viral variation or small …

… two-dose, or even one-dose, coverages still remain low in many areas of the world. Our
findings support mixed SARS-CoV-2 vaccine schedules and extended intervals between doses, …

… Coronaviruses are positive sense RNA viruses of which SARS-Coronavirus-2 (SARS-CoV-2)
is the most recently identified member and cause of COVID-19. Previous work has shown …

… Using data from all participants in the national survey 22 , we found a 76% reduction in
symptomatic SARS-CoV-2 infection following a first vaccine dose, rising to 95% after two …

… Although a decline in protection against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection after two doses of BNT162b2 vaccine (Pfizer–BioNTech) has been …

… or lower dosage effect ω = 20 (keeping interval τ = 2 fixed, as in Figure 3), in both the cases,
infection remains present in the system. Thus, the proper dosage of drug and optimal dosing …